Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions

Imaging the location and extent of cancer provides invaluable information before, during, and after surgery. The majority of “image-guided” methods that use, for example, positron emission tomography (PET) involve preoperative imaging and do not provide real-time information during surgery. It is no...

Full description

Saved in:
Bibliographic Details
Main Authors: Jason P. Holland, Guillaume Normand, Alessandro Ruggiero, Jason S. Lewis, Jan Grimm
Format: Article
Language:English
Published: SAGE Publishing 2011-05-01
Series:Molecular Imaging
Online Access:https://doi.org/10.2310/7290.2010.00047
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841561800739389440
author Jason P. Holland
Guillaume Normand
Alessandro Ruggiero
Jason S. Lewis
Jan Grimm
author_facet Jason P. Holland
Guillaume Normand
Alessandro Ruggiero
Jason S. Lewis
Jan Grimm
author_sort Jason P. Holland
collection DOAJ
description Imaging the location and extent of cancer provides invaluable information before, during, and after surgery. The majority of “image-guided” methods that use, for example, positron emission tomography (PET) involve preoperative imaging and do not provide real-time information during surgery. It is now well established that the inherent optical emissions (Cerenkov radiation) from various β-emitting radionuclides can be visualized by Cerenkov luminescence imaging (CLI). Here we report the full characterization of CLI using the positron-emitting radiotracer 89 Zr-DFO-trastuzumab for target-specific, quantitative imaging of HER2/neu -positive tumors in vivo. We also provide the first demonstration of the feasibility of using CLI for true image-guided, intraoperative surgical resection of tumors. Analysis of optical CLIs provided accurate, quantitative information on radiotracer biodistribution and tissue uptake that correlated well with the concordant PET images. CLI, PET, and biodistribution studies revealed target-specific uptake of 89 Zr-DFO-trastuzumab in BT-474 ( HER2/neu positive) versus MDA-MB-468 ( HER2/neu negative) xenografts in the same mice. Competitive inhibition (blocking) studies followed by CLI also confirmed the in vivo immunoreactivity and specificity of 89 Zr-DFO-trastuzumab for HER2/neu . Overall, these results strongly support the continued development of CLI as a preclinical and possible clinical tool for use in molecular imaging and surgical procedures for accurately defining tumor margins.
format Article
id doaj-art-b287d130c62a4d0ebfec04b5e3b19480
institution Kabale University
issn 1536-0121
language English
publishDate 2011-05-01
publisher SAGE Publishing
record_format Article
series Molecular Imaging
spelling doaj-art-b287d130c62a4d0ebfec04b5e3b194802025-01-03T01:24:45ZengSAGE PublishingMolecular Imaging1536-01212011-05-011010.2310/7290.2010.0004710.2310_7290.2010.00047Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence EmissionsJason P. HollandGuillaume NormandAlessandro RuggieroJason S. LewisJan GrimmImaging the location and extent of cancer provides invaluable information before, during, and after surgery. The majority of “image-guided” methods that use, for example, positron emission tomography (PET) involve preoperative imaging and do not provide real-time information during surgery. It is now well established that the inherent optical emissions (Cerenkov radiation) from various β-emitting radionuclides can be visualized by Cerenkov luminescence imaging (CLI). Here we report the full characterization of CLI using the positron-emitting radiotracer 89 Zr-DFO-trastuzumab for target-specific, quantitative imaging of HER2/neu -positive tumors in vivo. We also provide the first demonstration of the feasibility of using CLI for true image-guided, intraoperative surgical resection of tumors. Analysis of optical CLIs provided accurate, quantitative information on radiotracer biodistribution and tissue uptake that correlated well with the concordant PET images. CLI, PET, and biodistribution studies revealed target-specific uptake of 89 Zr-DFO-trastuzumab in BT-474 ( HER2/neu positive) versus MDA-MB-468 ( HER2/neu negative) xenografts in the same mice. Competitive inhibition (blocking) studies followed by CLI also confirmed the in vivo immunoreactivity and specificity of 89 Zr-DFO-trastuzumab for HER2/neu . Overall, these results strongly support the continued development of CLI as a preclinical and possible clinical tool for use in molecular imaging and surgical procedures for accurately defining tumor margins.https://doi.org/10.2310/7290.2010.00047
spellingShingle Jason P. Holland
Guillaume Normand
Alessandro Ruggiero
Jason S. Lewis
Jan Grimm
Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions
Molecular Imaging
title Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions
title_full Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions
title_fullStr Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions
title_full_unstemmed Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions
title_short Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions
title_sort intraoperative imaging of positron emission tomographic radiotracers using cerenkov luminescence emissions
url https://doi.org/10.2310/7290.2010.00047
work_keys_str_mv AT jasonpholland intraoperativeimagingofpositronemissiontomographicradiotracersusingcerenkovluminescenceemissions
AT guillaumenormand intraoperativeimagingofpositronemissiontomographicradiotracersusingcerenkovluminescenceemissions
AT alessandroruggiero intraoperativeimagingofpositronemissiontomographicradiotracersusingcerenkovluminescenceemissions
AT jasonslewis intraoperativeimagingofpositronemissiontomographicradiotracersusingcerenkovluminescenceemissions
AT jangrimm intraoperativeimagingofpositronemissiontomographicradiotracersusingcerenkovluminescenceemissions